Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - Findings from the EUROASPIRE IV survey

Creative Commons License

Reiner Z., De Backer G., Fras Z., Kotseva K., Tokgozoglu L., Wood D., ...More

ATHEROSCLEROSIS, vol.246, pp.243-250, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 246
  • Publication Date: 2016
  • Doi Number: 10.1016/j.atherosclerosis.2016.01.018
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.243-250
  • Hacettepe University Affiliated: Yes


Objective: Since dyslipidaemia is one of the most important risk factors for coronary heart disease (CHD), lowering of LDL-cholesterol (LDL-C) causes significant reduction in morbidity and mortality, particularly in patients with established CHD. The aim of this survey was to assess how statins were prescribed in CHD patients at discharge after a coronary event from hospitals throughout Europe and how the intake of these drugs was reported by the patients when they were seen more than one year later in relationship with their achieved LDL-C levels.